Interviews
View More
Expert Discusses How DMT Differs From Other Psychedelic Medicines

Carol Routledge, PhD, chief medical and scientific officer at Small Pharma, discusses DMT, how it differs from other psychedelic medicines, and what the future holds for DMT-assisted treatments.

New Molecules, Preclinical Data Show Promise for Treatment of AML, DLBCL

Data from a couple of new molecules could be encouraging for the treatment of acute myeloid leukemia and diffuse large B-cell lymphoma

Expert: Totality of Current Data Support the Use of Acalabrutinib in Patients With CLL

In addition to data showing the durable efficacy of acalabrutinib, other data presented at ASH 2021 demonstrate that the new tablet formulation of the drug supports ease of use for patients

Studies Show Acalabrutinib Is Well-Tolerated in Patients with CLL

Most adverse effects are very tolerable and easily managed, including headaches, diarrhea, and some neutropenias or infections

Expert Discusses Key Findings of Longer Term Follow Up of iFCR Therapy Study for Chronic Lymphocytic Leukemia

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses the results of a longer-term follow up for iFCR therapy for individuals with chronic lymphocytic leukemia .

Acalabrutinib Could Be Particularly Impactful for Long-Term Treatment Perspectives in CLL

Acalabrutinib could offer a high level of confidence for patients looking at a long course of disease.

Expert: Chronic Lymphocytic Leukemia Can Effect Younger Individuals

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how common chronic lymphocytic leukemia is for younger individuals

Individuals With Chronic Lymphocytic Leukemia Benefit More From iFCR Therapy Than Older Individuals

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses how the results of a longer term study differ for individuals who were younger with chronic lymphocytic leukemia as opposed to those who are older.

Expert Discussed Long Term iFCR Therapy Follow Up for Younger Individuals With Chronic Lymphocytic Leukemia

Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses what the results of the initial iFCR study showed and what the highlights of the longer-term follow up were for individuals with chronic lymphocytic leukemia.

Official Media Partner

Official Media Partner

Official CE Partner

Official CE Partner

Founder of Women Pharmacist Day

Founder of Women Pharmacist Day
pharmacist moms group logo
Stay In Touch
an mjh life sciences brand

© 2021 MJH Life Sciences and Pharmacy Times®. All rights reserved.

Privacy Policy